X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) has announced the issuance of inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. The awards consist of options to purchase 396,824 shares of common stock at an exercise price of $0.371 per share, equal to the closing price on December 2, 2024.
The options have a ten-year term and will vest over four years, with 25% vesting after 12 months and the remainder vesting monthly over the following 36 months, contingent on continued employment. These awards were granted as inducement material for new employees and approved by X4's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
X4 Pharmaceuticals (XFOR) ha annunciato l'emissione di premi di indennità per i nuovi dipendenti ai sensi del suo Piano di Incentivazione Azionaria 2019. I premi consistono in opzioni per acquistare 396.824 azioni di azioni ordinarie a un prezzo di esercizio di $0.371 per azione, pari al prezzo di chiusura del 2 dicembre 2024.
Le opzioni hanno un termine di dieci anni e matureranno nell'arco di quattro anni, con il 25% che matura dopo 12 mesi e il restante che matura mensilmente nei successivi 36 mesi, subordinato alla continuazione dell'impiego. Questi premi sono stati concessi come incentivo per i nuovi dipendenti e approvati dal Comitato per la Compensazione di X4 in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
X4 Pharmaceuticals (XFOR) ha anunciado la emisión de premios de inducción para nuevos empleados bajo su Plan de Incentivos de Capital de Inducción de 2019. Los premios consisten en opciones para comprar 396,824 acciones de acciones ordinarias a un precio de ejercicio de $0.371 por acción, igual al precio de cierre del 2 de diciembre de 2024.
Las opciones tienen un plazo de diez años y se consolidarán durante cuatro años, con un 25% consolidándose después de 12 meses y el resto consolidándose mensualmente durante los siguientes 36 meses, condicionado a la continuación del empleo. Estos premios fueron otorgados como material de inducción para nuevos empleados y aprobados por el Comité de Compensación de X4 de acuerdo con la Regla de Listado Nasdaq 5635(c)(4).
X4 제약 (XFOR)는 2019년 유인 주식 인센티브 계획에 따라 신규 직원에게 유인 상금 발급을 발표했습니다. 이 상금은 396,824주의 보통주를 주당 $0.371의 행사 가격으로 구매하는 옵션으로 구성되어 있으며, 이는 2024년 12월 2일의 종가와 동일합니다.
옵션의 유효 기간은 10년이며, 4년에 걸쳐 분할 지급되며, 12개월 후 25%가 지급되고 나머지는 이후 36개월 동안 매달 지급됩니다. 이 상금은 신규 직원을 위한 유인 물질로 제공되었으며, 나스닥 상장규칙 5635(c)(4)에 따라 X4의 보상위원회에서 승인되었습니다.
X4 Pharmaceuticals (XFOR) a annoncé l'octroi de primes d'incitation aux nouveaux employés dans le cadre de son Plan d'Incitation à l'Équité de 2019. Les primes consistent en des options d'achat de 396.824 actions ordinaires à un prix d'exercice de $0.371 par action, équivalent au prix de clôture du 2 décembre 2024.
Les options ont une durée de dix ans et seront acquises sur quatre ans, avec 25% acquises après 12 mois et le reste acquis mensuellement durant les 36 mois suivants, sous réserve de la poursuite de l'emploi. Ces primes ont été accordées comme matériel d'incitation pour les nouveaux employés et approuvées par le Comité de Rémunération de X4 conformément à la Règle d'Inscription Nasdaq 5635(c)(4).
X4 Pharmaceuticals (XFOR) hat die Vergabe von Anreizprämien für neue Mitarbeiter im Rahmen seines Anreiz-Aktienoptionsplans 2019 bekannt gegeben. Die Prämien bestehen aus Optionen zum Kauf von 396.824 Aktien zu einem Ausübungspreis von $0.371 pro Aktie, was dem Schlusskurs vom 2. Dezember 2024 entspricht.
Die Optionen haben eine Laufzeit von zehn Jahren und werden über vier Jahre erdrosselt, wobei 25% nach 12 Monaten und der Rest monatlich über die folgenden 36 Monate fällig wird, vorausgesetzt die Beschäftigung bleibt bestehen. Diese Prämien wurden als Anreizmaterial für neue Mitarbeiter gewährt und vom Vergütungsausschuss von X4 gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- Low share price of $0.371 indicates potential financial concerns
- Stock option grants may lead to future shareholder dilution
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on December 2, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 396,824 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
How many shares were included in X4 Pharmaceuticals (XFOR) December 2024 inducement grants?
What is the exercise price for XFOR's December 2024 inducement stock options?
What is the vesting schedule for XFOR's December 2024 inducement options?
